diff --git a/archive-covid-19/16 December, 2020.html b/archive-covid-19/16 December, 2020.html new file mode 100644 index 0000000..c39f3dc --- /dev/null +++ b/archive-covid-19/16 December, 2020.html @@ -0,0 +1,213 @@ + +
+ + + ++We introduce a deep learning framework that can detect COVID-19 pneumonia in thoracic radiographs, as well as differentiate it from bacterial pneumonia infection. Deep classification models, such as convolutional neural networks (CNNs), require large-scale datasets in order to be trained and perform properly. Since the number of X-ray samples related to COVID-19 is limited, transfer learning (TL) appears as the go-to method to alleviate the demand for training data and develop accurate automated diagnosis models. In this context, networks are able to gain knowledge from pretrained networks on large-scale image datasets or alternative data-rich sources (i.e. bacterial and viral pneumonia radiographs). The experimental results indicate that the TL approach outperforms the performance obtained without TL, for the COVID-19 classification task in chest X-ray images. +
++Background This study aimed to investigate the impact of the first COVID-19 lockdown (March-April 2020) on risk for stress/depression and functional impairment in a representative sample of adult individuals in Denmark, and whether the impact of lockdown was heterogeneous across living situation. Methods: Using a representative, randomly drawn sample from the complete Danish adult population interviewed in March 2 to April 13, 2020 (n=2,836) and again in July 2020 (n=1,526, 54% retention rate), we study how the imposed lockdown announced March 11 following the onset of the first Danish wave of COVID-19 infections affected mental wellbeing. We use the World Health Organization Five Well-being Index (WHO-5) and the Work and Social Adjustment Scale (WSAS) to capture wellbeing and functioning. Using covariate adjusted ordinary least squares linear probability models and exploiting variation in the timing of responses occurring just before and just after the introduction of lockdown, we compare respondents before lockdown to respondents that answered during lockdown, as well to answers in re-interviews in July. Results: We find reduced depressive symptoms among adults immediately after the shutdown, concentrated in adults with children living at home. Measures of functional impairment also decline immediately after the March shutdown among adults with children living at home. Impairment intensified for the entire sample between March and July, but depressive symptoms remained at lower rate in July. Conclusions: Findings in Denmark indicate that living with children at home may have, in the short term, buffered the potential mental health sequelae of the COVID-19 shutdown. +
++Background: Older adults have been disproportionately affected by COVID-19, with high fatalities and health complications reported. Adults over the age of 70 in the UK were advised to self-isolate for 3 months early during the pandemic and it is unclear which factors influenced their experiences during this time. Objective: The aim of this qualitative study was to explore factors that threatened and protected the wellbeing of older adults living in the UK during the COVID-19 pandemic. Methods: We undertook semi-structured interviews with 20 adults aged over 70. Purposive sampling methods were used to increase diversity within the group. Transcripts were analysed using thematic analysis. Results: Participants were aged 72-93, 9 women and 11 men, 80% were White British, 40% lived alone. We identified 2 superordinate themes, including (1) Threats to wellbeing: mortality concerns, grief and loss of normal life, restricted health service access, COVID-19 concerns, and restricted access to activities that protect wellbeing. (2) Factors protective of wellbeing: slower pace of life, maintaining routine, socialising, and use of past coping skills. Many participants drew on their resilience and life experience to self-manage fear and uncertainty associated with the pandemic, using their time during lockdown to reflect or organise end-of-life affairs. Conclusions: This study provides evidence that while older adults experienced challenges, many were resilient against COVID-19 restrictions despite early concerns of mental health consequences. Our findings highlight the importance of maintaining access to essentials to promote feelings of normality and social support to help reduce uncertainty in times of pandemics. +
++Introduction: Rapid, high throughput diagnostics are a valuable tool, allowing the detection of SARS-CoV-2 in populations, in order to identify and isolate people with asymptomatic and symptomatic infections. Reagent shortages and restricted access to high throughput testing solutions have limited the effectiveness of conventional assays such as reverse transcriptase quantitative PCR (RTqPCR), particularly throughout the first months of the pandemic. We investigated the use of LamPORE, where loop mediated isothermal amplification (LAMP) is coupled to nanopore sequencing technology, for the detection of SARS CoV 2 in symptomatic and asymptomatic populations. Methods: In an asymptomatic prospective cohort; health care workers across four sites (Birmingham, Southampton, Basingstoke and Manchester) self swabbed with nasopharyngeal swabs weekly for three weeks and supplied a saliva specimen daily. These samples were tested for SARS CoV 2 RNA using the Oxford Nanopore LamPORE system and a reference RTqPCR assay on extracted sample RNA. A second retrospective cohort of 848 patients with influenza like illness from March 2020 to June 2020, were similarly tested from nasopharyngeal swabs. Results: In the asymptomatic cohort a total of 1200 participants supplied 23,427 samples (3,966 swab, 19,461 saliva) over a three-week period. The incidence of SARS CoV 2 was 0.95% using LamPORE. Diagnostic sensitivity and specificity was > 99.5% in both swab and saliva asymptomatic samples as compared to the reference RTqPCR test. In the retrospective symptomatic cohort, the incidence was 13.4% and the sensitivity and specificity were 100%. Conclusions: LamPORE is a highly accurate methodology for the detection of SARS CoV 2 in both the symptomatic and asymptomatic population settings and can be used as an alternative to RTqPCR. +
++Introduction: The Coronavirus (COVID-19) Pandemic has caused significant global mortality and impacted lives around the world. Virus Watch aims to provide evidence on which public health approaches are most likely to be effective in reducing transmission and impact of the virus, and will investigate community incidence, symptom profiles, and transmission of COVID-19 in relation to population movement and behaviours. Methods and analysis: Virus Watch is a household community cohort study of acute respiratory infections in England & Wales and will run from June 2020 to Sept 2021. The study aims to recruit 42,500 people, including 12,500 from minority ethnic backgrounds, for an online survey cohort. Nested within this larger study will be a sub-cohort of 10,000 individuals, including 3,000 people from minority ethnic backgrounds. This cohort of 10,000 people will have full blood serology taken between October 2020 and January 2021 and repeat serology between May 2021 and August 2021. Participants will also post self-administered nasal swabs for PCR assays of SARS-CoV-2 and will follow one of three different PCR testing schedules based upon symptoms. Ethics and dissemination: This study has been approved by the Hampstead NHS Health Research Authority Ethics Committee. Ethics approval number - 20/HRA/2320. We are monitoring participant queries and using these to refine methodology where necessary, and are providing summaries of our preliminary findings to inform public health action by working through partnerships with our study advisory group, Public Health England, NHS and Government Scientific Advisory panels. +
++As increasing numbers of people recover from and are vaccinated against COVID-19, tests are needed to measure levels of protective, neutralizing antibodies longitudinally to help determine duration of immunity. We developed a lateral flow assay (LFA) that measures levels of neutralizing antibodies in plasma, serum or whole blood. The LFA is based on the principle that neutralizing antibodies inhibit binding of the spike protein receptor-binding domain (RBD) to angiotensin-converting enzyme 2 (ACE2). The test classifies high levels of neutralizing antibodies in sera that were titered using authentic SARS-CoV-2 and pseudotype neutralization assays with an accuracy of 98%. Sera obtained from patients with seasonal coronavirus did not prevent RBD from binding to ACE2. As a demonstration for convalescent plasma therapy, we measured conversion of non-immune plasma into strongly neutralizing plasma. This is the first report of a neutralizing antibody test that is rapid, highly portable and relatively inexpensive that might be useful in assessing COVID-19 vaccine immunity. +
++The need to identify and effectively treat COVID-19 cases at highest risk for severe disease is critical. We identified seven common genetic variants (three novel) that modulate COVID-19 susceptibility and severity, implicating IFNAR2, CCHCR1, TCF19, SLC6A20 and the hyaluronan pathway as potential therapeutic targets. A high genetic burden was strongly associated with increased risk of hospitalization and severe disease among COVID-19 cases, especially among individuals with few known risk factors. +
++Background Sufficient community testing for suspected COVID-19 regardless of residential area is essential for a successful test-trace-isolate strategy. Aim This study aimed to elucidate area level characteristics linked to testing rates. Methods Free-of-charge diagnostic tests (PCR) of SARS-CoV-2 was made available to the general public in late June 2020 in Uppsala County, Sweden, at four main test stations, and to a lesser extent at other health care units. We analysed 35,794 tests performed on individuals from 346 postal codes, from 24 June to 12 October 2020. Results We observed varying testing rates across postal code areas within Uppsala City as well as in Uppsala County. Testing rates were lower in areas characterized by longer distance to the nearest test station, lower neighbourhood deprivation index indicating higher deprivation (NDI) and higher proportion of inhabitants with foreign background. Multivariable regression models could not separate influences of foreign background and NDI on COVID-19 testing rates as these were collinear. Further, we did not detect any association between COVID-19 hospitalization rates and testing rates, indicating that underlying community infection rates did not substantially affect test frequency during this period. Conclusion We observed that testing rates were associated with distance to test station and socioeconomic and demographic circumstances. As lower testing rates can contribute to inequity in pandemic health effects, there is an urgent need to ensure adequate test accessibility in all parts of society. +
++Objectives: Currently used prognostic tools for patients with SARS-CoV-2 infection are based on clinical and laboratory parameters measured at a single point in time, usually on admission. We aimed to determine how dynamic changes in clinical and laboratory parameters relate to SARS-CoV-2 prognosis. Design: retrospective, observational cohort study using routinely collected clinical data to model the dynamic change in prognosis of SARS-CoV-2. Setting: a single, large hospital in England. Participants: all patients with confirmed SARS-CoV-2 admitted to Nottingham University Hospitals (NUH) NHS Trust, UK from 1st February 2020 until 30th November 2020. Main outcome measures: Intensive Care Unit (ICU) admission, death and discharge from hospital. Statistical Methods: We split patients into 1st (admissions until 30th June) and 2nd (admissions thereafter) waves. We incorporated all clinical observations, blood tests and other covariates from electronic patient records and follow up until death or 30 days from the point of hospital discharge. We modelled daily risk of admission to ICU or death with a time varying Cox proportional hazards model. Results: 2,964 patients with confirmed SARS-CoV-2 were included. Of 1,374 admitted during the 1st wave, 593 were eligible for ICU escalation, and 466 had near complete ascertainment of all covariates at admission. Our validation sample included 1,590 confirmed cases, of whom 958 were eligible for ICU admission. Our model had good discrimination of daily need for ICU admission or death (C statistic = 0.87 (IQR 0.85-0.90)) and predicted this daily prognosis better than previously published scores (NEWS2, ISCARIC 4C). In validation in the 2nd wave the score overestimated escalation (calibration slope 0.55), whilst retaining a linear relationship and good discrimination (C statistic = 0.88 (95% CI 0.81 -0.95)). Conclusions: A bespoke SARS-CoV-2 escalation risk prediction score can predict need for clinical escalation better than a generic early warning score or a single estimation of risk at admission. +
++In November 2020, we conducted a cross sectional study to implement and test the method of acquaintance sampling (randomly sampling friends of randomly sampled individuals) in detecting students with higher probability of COVID-19 positivity. Overall, 879 students were randomly sampled and participated in this study. In an online survey, the randomly sampled participants nominated a friend, and reported their own and their nominated friend9s COVID-19 status. Nominated friends were about 1.64 (95% CI: 1.33, 2.00) times more likely to have ever been infected with COVID-19, compared to randomly sampled students. Our study corroborates the effectiveness of acquaintance sampling for identifying members of networks with higher COVID-19 risk. These findings could be useful for university policy makers when developing mitigation testing programs and intervention strategies against COVID-19 spread. +
++Background: The COVID-19 lockdown increases psychological problems in children and adolescents from the general population. Here we investigate the mental and social health during the COVID-19 lockdown in children and adolescents with pre-existing mental or somatic problems. Method: We included participants (8-18 years) from a psychiatric (N = 249) and pediatric (N = 90) sample, and compared them to a general population sample (N = 844). Measures were assessed during the first lockdown (April-May 2020) in the Netherlands. Main outcome measures were Patient-Reported Outcomes Measurement Information System (PROMIS) domains: Global Health, Peer Relationships, Anxiety, Depressive Symptoms, Anger, and Sleep-Related Impairment. Additionally, socio-demographic variables, COVID-19-related questions, changes in atmosphere at home from a parent and child perspective, and children9s experiences of lockdown regulations were assessed. Results: On all measures except Global Health, the pediatric sample reported least problems. The psychiatric sample reported significantly more problems than the general population sample on all measures except for Anxiety and Peer Relationships. Having a COVID-19 affected friend/relative and a COVID-19 related change in work situation negatively moderated outcome, but not in the samples with pre-existing problems. All parents reported significant decreases in atmosphere at home, as did children from the general population. Conclusion: We observed significant differences in mental and social health between three child and adolescent samples during the COVID-19 pandemic lockdown and identified COVID-19-related factors influencing mental and social health. Our findings contribute to current and future policies during pandemic related lockdowns regarding the mental and social health of children and adolescents. +
++The results of COVID-19 vaccine clinical trials suggest that an end to the pandemic is within reach. However, public health authorities worldwide are faced with the difficult task of prioritizing their allocation. Theory indicates that prioritizing vaccination of individuals with more contacts can be disproportionately effective. However, implementation of such strategies has been hampered by inability to determine population contact structure. One of the novel tools introduced during the pandemic has been the use of Bluetooth technology to assist in contact tracing and exposure notification. Here we show that the technology underlying these Bluetooth exposure notification applications can be leveraged to efficiently prioritise vaccine allocation. Our approach is based on the insight that these apps also act as local sensing devices measuring each user9s total exposure time to other app users, thereby enabling the implementation of a previously impossible vaccine strategy that prioritises potential super-spreaders based on total exposure time. To compare vaccination strategies we introduce a novel and widely generalizable measure of vaccination efficiency. By extending percolation theory we furthermore demonstrate that our proposed 99hot-spotting" strategy can achieve herd immunity with less than half as many vaccines as distributing the vaccines uniformly in the population. +
++A mathematical model of the spread of the Covid-19 in the Democratic Republic of the Congo taking into account the vulnerability of the economy is proposed. The reproduction number of the Covid-19 is calculated and numerical simulations are performed using Python software. Clear advice for the policymakers is deduced from the forecasting of the model. +
++Widespread diagnostic testing is needed to reduce transmission of COVID-19 and manage the pandemic. Effective mass screening requires robust and sensitive tests that reliably detect the SARS-CoV-2 virus, including asymptomatic and pre-symptomatic infections with a low viral count. Currently, the most accurate tests are based on detection of viral RNA by RT-PCR. We developed a method to process COVID-19 specimens that simplifies and increases the sensitivity of viral RNA detection by direct RT-qPCR, performed without RNA purification. In the method, termed Alkaline-Glycol Processing (AG processing), a SARS-CoV-2-containing biological specimen, such as saliva or a swab-collected suspension, is processed at pH 12.2 to 12.8 for 5 min at room temperature. An aliquot of the AG-processed specimen is used for detection of SARS-CoV-2 RNA by direct RT-qPCR. AG processing effectively lyses viruses and reduces the effect of inhibitors of RT-PCR that are present in biological specimens. The sensitivity of detecting viral RNA using AG processing is on par with methods that include a viral RNA purification step. One copy of SARS-CoV-2 virus per reaction, equivalent to 300 copies per ml of saliva, is detectable in the AG-processed saliva. The LOD calculated following U.S. FDA guidelines is 600 viral copies per ml of initial saliva specimen. AG processing works with saliva specimens or swab specimens collected into Universal Transport Medium (UTM), is compatible with heat treatment, and was confirmed to work with a range of CDC-approved RT-qPCR products and kits. Detection of SARS-CoV-2 RNA using AG processing with direct RT-qPCR provides a reliable and scalable diagnostic test for COVID-19 that can be integrated into a range of workflows, including automated settings. +
++Importance: The development and importance of ambulatory hypoxia in COVID-19 is unknown. The presence of ambulatory hypoxia may help risk-stratify hospitalized patients with COVID-19. If sufficient lead-time exists between development of ambulatory hypoxia and other outcome measures, interventions might be initiated earlier. Objective: To determine the association of ambulatory hypoxia with the eventual need for nasal cannula or advanced oxygenation therapies (defined as use of high flow nasal cannula, Bi-PAP, ventilator, or extracorporeal membrane oxygenation). Design: Retrospective, observational study of patients hospitalized with COVID-19 from March 1, 2020 to October 30, 2020. Setting: Ten hospitals in an integrated academic medical system (Northwestern Medicine) in the Chicagoland area. Participants: Adult patients (age > 18) hospitalized for COVID-19 who had ambulatory oximetry measured. Intervention(s) / Exposure(s): Ambulatory oximetry measurement. Main outcomes and measures: The association of ambulatory hypoxia with subsequent use of nasal cannula and advanced oxygen therapies and the time between ambulatory hypoxia and need for these oxygen therapies. Patients who had ambulatory oximetry measurements after use of nasal cannula or advanced oxygen therapies were excluded. Results: Of 531 patients with ambulatory oximetry measured, 132 (24.9%) had ambulatory hypoxia. Presence of ambulatory hypoxia was strongly associated with subsequent use of nasal cannula (OR 4.8, 95% CI 2.8 - 8.4) and advanced oxygen therapy (IRR 7.7, 95% CI 3.4 - 17.5). Ambulatory hypoxia measurement preceded nasal cannula use by a median 12.5 hours [IQR 3.25, 29.25] and advanced oxygenation therapies by 54 hours [IQR 25, 82]. Conclusion and Relevance: Ambulatory hypoxia is associated with moderate to severe COVID-19. It may serve as an early, non-invasive physiologic marker for the likelihood of developing moderate to severe disease and help clinicians triage patients and initiate earlier interventions. +
+Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 - Condition: Covid19
Interventions: Drug: Silmitasertib; Drug: SOC
Sponsor: Chris Recknor, MD
Recruiting
Convalescent Plasma for Treatment of COVID-19: An Open Randomised Controlled Trial - Condition: Covid19
Interventions: Biological: SARS-CoV-2 convalescent plasma; Other: Standard of care
Sponsors: Joakim Dillner; Karolinska Institutet; Danderyd Hospital; Falu Hospital
Not yet recruiting
Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19) - Condition: COVID-19
Interventions: Biological: Group A (AG0302-COVID19); Biological: Group A (Placebo); Biological: Group B (AG0302-COVID19); Biological: Group B (Placebo)
Sponsors: AnGes, Inc.; Japan Agency for Medical Research and Development
Recruiting
Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers - Condition: COVID 19 Vaccine
Intervention: Biological: BCG vaccine
Sponsors: Universidade Federal do Rio de Janeiro; Ministry of Science and Technology, Brazil
Recruiting
At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19 - Condition: Covid19
Intervention: Drug: bamlanivimab
Sponsors: Daniel Griffin, MD PhD; Eli Lilly and Company; Optum, Inc.
Not yet recruiting
Changes in Viral Load in COVID-19 After Probiotics - Condition: COVID-19
Intervention: Dietary Supplement: Dietary supplementation with probiotic GASTEEL PLUS in patients with covid disease admitted to hospital
Sponsors: Hospital de Sagunto; Biopolis S.L.; Laboratorios Heel España
Recruiting
Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19) - Condition: COVID-19
Interventions: Drug: Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C; Drug: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose; Drug: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment
Sponsor: Xi'an International Medical Center Hospital
Active, not recruiting
COVID-19 And Geko Evaluation: The CAGE Study - Condition: Covid19
Intervention: Device: geko T3
Sponsor: Lawson Health Research Institute
Not yet recruiting
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection - Condition: Covid19
Intervention: Biological: AT-100
Sponsor: Airway Therapeutics, Inc.
Not yet recruiting
LYT-100 in Post-acute COVID-19 Respiratory Disease - Condition: Covid19
Interventions: Drug: LYT-100; Other: Placebo
Sponsors: PureTech; Clinipace Worldwide; Novotech (Australia) Pty Limited
Not yet recruiting
COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis - Condition: Covid19
Interventions: Drug: Apixaban 2.5 MG; Drug: Placebo
Sponsors: Thomas Ortel, M.D., Ph.D.; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting
Mushroom-based Product for COVID-19 - Condition: COVID-19
Intervention: Drug: FoTv
Sponsors: Gordon Saxe; University of California, Los Angeles; University of California, Irvine
Recruiting
Urine Alkalinisation to Prevent AKI in COVID-19 - Condition: Covid19
Intervention: Drug: Sodium Bicarbonate 150Meq/L/D5W Inj
Sponsor: Guy's and St Thomas' NHS Foundation Trust
Not yet recruiting
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol - Condition: Covid19
Interventions: Drug: Acebilustat; Drug: Camostat
Sponsor: Stanford University
Not yet recruiting
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol - Condition: Covid19
Interventions: Drug: Camostat; Drug: Placebo
Sponsor: Stanford University
Not yet recruiting
Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review - World Health Organization (WHO) declared coronavirus disease (COVID-19) a pandemic in March 2020. Currently almost every country in the world has reported cases with moderate to high mortality rates. The European Union (EU), the United States of America (USA) and the United Kingdom (UK) are the severely affected countries. Nevertheless, the WHO is very much concern about countries with weak health systems. The clinical characteristics of COVID-19 varies extensively, ranging from asymptomatic...
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2 - A consensus virtual screening protocol has been applied to ca. 2000 approved drugs to seek inhibitors of the main protease (M^(pro)) of SARS-CoV-2, the virus responsible for COVID-19. 42 drugs emerged as top candidates, and after visual analyses of the predicted structures of their complexes with M^(pro), 17 were chosen for evaluation in a kinetic assay for M^(pro) inhibition. Remarkably 14 of the compounds at 100-μM concentration were found to reduce the enzymatic activity and 5 provided IC(50)...
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2 - COVID-19 pandemic has infected millions of people with mortality exceeding >1 million. There is an urgent need to find therapeutic agents that can help clear the virus to prevent severe disease and death. Identifying effective and safer drugs can provide more options to treat COVID-19 infections either alone or in combination. Here, we performed a high throughput screening of approximately 1,700 US FDA-approved compounds to identify novel therapeutic agents that can effectively inhibit...
Possible Role of Adenosine in COVID-19 Pathogenesis and Therapeutic Opportunities - The outbreak of the novel coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2) requires urgent clinical interventions. Crucial clinical needs are: 1) prevention of infection and spread of the virus within lung epithelia and between people, 2) attenuation of excessive lung injury in Advanced Respiratory Distress Syndrome, which develops during the end stage of the disease, and 3) prevention of thrombosis associated with SARS-CoV-2 infection....
Deciphering the Pharmacological Mechanisms of Ma Xing Shi Gan Decoction against COVID-19 through Integrating Network Pharmacology and Experimental Exploration - The outbreak of new infectious pneumonia caused by SARS-CoV-2 has posed a significant threat to public health, but specific medicines and vaccines are still being developed. Traditional Chinese medicine (TCM) has thousands of years of experience in facing the epidemic disease, such as influenza and viral pneumonia. In this study, we revealed the efficacy and pharmacological mechanism of Ma Xing Shi Gan (MXSG) Decoction against COVID-19. First, we used liquid chromatography-electrospray...
Taming the Autophagy as a Strategy for Treating COVID-19 - Currently, an efficient treatment for COVID-19 is still unavailable, and people are continuing to die from complications associated with SARS-CoV-2 infection. Thus, the development of new therapeutic approaches is urgently needed, and one alternative is to target the mechanisms of autophagy. Due to its multifaceted role in physiological processes, many questions remain unanswered about the possible advantages of inhibiting or activating autophagy. Based on a search of the literature in this...
A Computer-Aided Drug Design Approach to Predict Marine Drug-Like Leads for SARS-CoV-2 Main Protease Inhibition - The investigation of marine natural products (MNPs) as key resources for the discovery of drugs to mitigate the COVID-19 pandemic is a developing field. In this work, computer-aided drug design (CADD) approaches comprising ligand- and structure-based methods were explored for predicting SARS-CoV-2 main protease (M^(pro)) inhibitors. The CADD ligand-based method used a quantitative structure-activity relationship (QSAR) classification model that was built using 5276 organic molecules extracted...
The role of extracellular DNA in COVID-19: clues from inflamm-aging - Epidemiological data convey severe prognosis and high mortality rate for COVID-19 in elderly men affected by age-related diseases. These subjects develop local and systemic hyper-inflammation, which are associated with thrombotic complications and multi-organ failure. Therefore, understanding SARS-CoV-2 induced hyper-inflammation in elderly men is a pressing need. Here we focus on the role of extracellular DNA, mainly mitochondrial DNA (mtDNA) and telomeric DNA (telDNA) in the modulation of...
Dual Targeting of 3CL(pro) and PL(pro) of SARS-CoV-2: A Novel Structure-Based Design Approach to treat COVID-19 - With the rapid growth of the COVID-19 (coronavirus disease 2019) pandemic across the globe, therapeutic attention must be directed to fight the novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). However, developing new antiviral drugs and vaccine development is time-consuming, so one of the best solutions to tackle this virus at present is to repurpose ready-to-use drugs. This paper proposes the repurposing of the Food and Drug Administration (FDA)-approved, purchasable, and...
Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2 - The SARS-CoV-2 infection is spreading rapidly worldwide. Efficacious antiviral therapeutics against SARS-CoV-2 is urgently needed. Here, we discovered that protoporphyrin IX (PpIX) and verteporfin, two FDA-approved drugs, completely inhibited the cytopathic effect produced by SARS-CoV-2 infection at 1.25 µmol/Land 0.31 µmol/L respectively, and their EC50 values of reduction of viral RNA were at nanomolar concentrations. The selectivity indices of PpIX and verteporfin were 952.74 and 368.93,...
Autophagy in T cells from aged donors is maintained by spermidine, and correlates with function and vaccine responses - Older adults are at high risk for infectious diseases such as observed at the recent COVID-19 outbreak and vaccination seems to be the only long-term solution to the pandemic. While most vaccines are less efficacious in older adults, little is known about the molecular mechanisms that underpin this. Autophagy, a major degradation pathway and one of the few processes known to prevent aging, is critical for the maintenance of immune memory in mice. Here, we show that autophagy is specifically...
mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses - In this commentary, we shed light on the role of the mammalian target of rapamycin (mTOR) pathway in viral infections. The mTOR pathway has been demonstrated to be modulated in numerous RNA viruses. Frequently, inhibiting mTOR results in suppression of virus growth and replication. Recent evidence points towards modulation of mTOR in SARS-Cov2 infection. We discuss the current literature on mTOR in SARS-Cov2 and highlight evidence in support of a role for mTOR inhibitors in the treatment of...
Host metabolism dysregulation and cell tropism identification in human airway and alveolar organoids upon SARS-CoV-2 infection - The coronavirus disease 2019 (COVID-19) pandemic is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is spread primary via respiratory droplets and infects the lungs. Currently widely used cell lines and animals are unable to accurately mimic human physiological conditions because of the abnormal status of cell lines (transformed or cancer cells) and species differences between animals and humans. Organoids are stem cell-derived self-organized...
HMGB1 as a potential biomarker and therapeutic target for severe COVID-19 - COVID-19 has attracted global attention due to its rapid spread around the world with substantial morbidity and associated mortality. Severe COVID-19 can be complicated by the acute respiratory distress syndrome, sepsis and septic shock leading to death. These complications are thought to result from an overactivation of the immune system, leading to a cytokine storm syndrome associated with multiple organ failure. Here, we report that high mobility group box 1 (HMGB1), a prototypical...
Age-dependent possible role of contact-activated blood coagulation factor XII as a potential contributor to the "bradykinin storm" in COVID-19 patients - CONCLUSION: The targeted inhibition of activated blood coagulation factor XII may represent a new therapeutic target for COVID-19, especially for elder patients. Recently, beneficial results have already been observed by the clinical applications of recombinant C1INH and bradykinin receptor antagonists. Orv Hetil. 2020; 161(50): 2099-2103.
"AYURVEDIC PROPRIETARY MEDICINE FOR TREATMENT OF SEVERWE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2." - AbstractAyurvedic Proprietary Medicine for treatment of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)In one of the aspect of the present invention it is provided that Polyherbal combinations called Coufex (syrup) is prepared as Ayurvedic Proprietary Medicine , Aqueous Extracts Mixing with Sugar Syrup form the following herbal aqueous extract coriandrum sativum was used for the formulation of protek.Further another Polyherbal combination protek as syrup is prepared by the combining an aqueous extract of the medicinal herbs including Emblica officinalis, Terminalia chebula, Terminalia belerica, Aegle marmelos, Zingiber officinale, Ocimum sanctum, Adatoda zeylanica, Piper lingum, Andrographis panivulata, Coriandrum sativum, Tinospora cordiofolia, cuminum cyminum,piper nigrum was used for the formulation of Coufex.
Haptens, hapten conjugates, compositions thereof and method for their preparation and use - A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.
疫苗融合蛋白 - 本申请涉及一种融合蛋白,所述融合蛋白包括SARS‑CoV‑2抗原多肽和鞭毛蛋白或其片段。本申请还提供了所述融合蛋白的制备方法和用途。本申请所述的融合蛋白能够诱导机体产生针对SARS‑CoV类病毒的抗原的细胞免疫反应。
AN EFFICIENT METHODOLOGY TO MANAGE THE ADMISSIONS IN HOSPITALS DURING THE PANDEMICS SUCH AS COVID 19 -
一种SARS-CoV-2假病毒小鼠体内包装系统及其制备方法 - 本发明提供了一种假病毒小鼠体内包装系统的制备方法,包括以下步骤:S1基于慢病毒包装质粒系统和睡美人转座子系统构建SARS‑CoV‑2假病毒包装质粒系统,S2将步骤S1中SARS‑CoV‑2假病毒包装质粒系统与睡美人转座酶表达质粒混合通过水动力注射的方式转染小鼠肝细胞,然后睡美人转座子系统将SARS‑CoV‑2假病毒包装所需序列以剪切粘贴的方式整合到小鼠肝细胞的基因组。本发明可在小鼠体内持续制造分泌SARS‑CoV‑2假病毒,可模拟靶器官被SARS‑CoV‑2病毒持续侵入攻击的过程,从而可模拟出新冠肺炎(COVID‑19)的病理特征。基于SARS‑CoV‑2假病毒小鼠体内包装系统的动物模型安全性高,不需要P3级实验室就能开展研究。利用水动力注射的方式引入SARS‑CoV‑2假病毒包装质粒系统操作简单,成本低。
柴胡解毒药物组合物及其制备方法和应用 - 本发明属于中药领域,具体涉及一种柴胡解毒药物组合物及其制备方法和应用,所述柴胡解毒药物组合物以质量份计由如下原料组分制成:柴胡3060份,黄芩1530份,法半夏1530份,生姜1530份,大枣510份,枳实2040份,大黄1020份,桃仁1020份,白芍15~30份。本发明的柴胡解毒药物组合物能够显著改善普通型COVID‑19引起的咳嗽;能改善疫毒闭肺型重型COVID‑19引起的咳嗽,显著改善疫毒闭肺型重型COVID‑19引起的胸闷、气短和乏力等主要症状。另外经大量临床观察,本发明的柴胡解毒药物组合物能够显著改善疫毒闭肺型重型COVID‑19引起的发热面红,咳嗽,痰黄粘少,或痰中带血,喘憋气促,疲乏倦怠,口干苦粘,大便不畅,小便短赤等症状。
一种新型冠状病毒RBD核苷酸序列、优化方法与应用 - 本发明公开了一种新型冠状病毒RBD核苷酸序列、优化方法与应用。属于基因工程技术领域。优化步骤:(1)对野生型新型冠状病毒RBD核苷酸序列进行初步优化;(2)将宿主细胞特异性高表达分泌蛋白信号肽序列进行优化;(3)将人IgG1‑Fc核苷酸序列进行优化;(4)将步骤(2)优化后的宿主细胞特异性高表达分泌蛋白信号肽核苷酸序列、步骤(1)得到的初步优化新型冠状病毒RBD核苷酸序列、连接子核苷酸序列和步骤(3)优化后的人IgG1‑Fc核苷酸序列依次连接即可。与现有技术相比,本发明的有益效果:产生的克隆表达效率比野生新型冠状病毒RBD序列提高了约12倍,比中国仓鼠密码子偏性优化序列克隆表达效率提高了2倍。
ASSISTING COMPLEX FOR TAKING OF BIOMATERIAL FROM MOUTH IN PANDEMIC CONDITIONS - FIELD: medicine. SUBSTANCE: invention refers to medicine, namely to methods for contactless taking of biomaterial in tested person. Taking the biomaterial in the tested person is carried out in a room located in a dirty zone and separated by a partition from the clean zone, in which there is a laboratory assistant performing the procedure using a robotic complex. Complex includes digital controller, manipulator with tool unit, small manipulator, camera, monitor, control system of digital controller, manipulator, small manipulator, and complex control system. In the partition there are two holes: one – for installation and passage of the swab, the other – for the test tube installation. In the dirty zone there is a small manipulator having two actuators: one for movement of a test tube with a swab, and the second for positioning and placing a disposable mouthpiece. EFFECT: reduced risk of laboratory assistant and tested person infection by avoiding their direct contact. 17 cl, 1 dwg
+Einzeldosierte, wasserlösliche oder wassermischbare Arzneiform, umfassend mindestens einen antiinfektiven Arzneistoff, zur Herstellung einer Nasenspülung und/oder zur Verwendung in der lokalen Behandlung des menschlichen Nasenraums. +
+Einzeldosierte, wasserlösliche oder wassermischbare Arzneiform, umfassend mindestens einen antiinfektiven Arzneistoff, zur Herstellung einer Nasenspülung und/oder zur Verwendung in der lokalen Behandlung des menschlichen Nasenraums. +
The G.O.P. Can No Longer Be Relied On to Protect Democracy - The gall of Kevin McCarthy and his fellow-backers of Trump’s attempts to overturn the results of the election is only surpassed by their irresponsibility and fecklessness. - link
Sviatlana Tsikhanouskaya Is Overcoming Her Fears - “Every country has its own path to democracy,” Tsikhanouskaya, who calls herself the leader of democratic Belarus, says. “And this is ours.” - link
The Supreme Court Rejects Texas’s Shameful Lawsuit, But There Has to Be a Reckoning - If prominent Republicans don’t renounce Trump’s campaign to overturn the election, they will do lasting harm to the country—and the early signs are not good. - link
Trump’s Coup Attempt Isn’t Over - A challenge to the election result on the floor of Congress is guaranteed to fail, but it will afford Republicans a loud show of doing something to “stop the steal.” - link
The Overlooked Hallmark of the Trump Administration—and Other Autocracies - We generally understand the President’s failures as the products of cruelty and incompetence. But there is a third source: indifference. - link
+New climate commitments from China, the UK, and US bring the world closer to the Paris goals. +
++A series of announcements over the weekend at a United Nations climate summit has bolstered hope that global emissions may still fall in line with the goals of the Paris agreement, heading off the more severe effects of climate change. These new pledges come in a year that was bound to be a significant test for the global agreement, even before the Trump administration's withdrawal from it and the global spread of Covid-19. +
++First, let’s rewind. Five years ago, 195 countries came together to forge the Paris accord after decades of failed attempts to comprehensively address climate change. The countries — including the US — collectively agreed to reduce greenhouse gas emissions in line with holding average global temperature rise below 2 degrees Celsius (with an aim of 1.5 degrees) to keep climate change in check. +
++But even with that goal established, whether countries voluntarily pursued it in earnest was always a gamble. The nonbinding agreement is structured so that countries themselves determine how fast to cut their emissions; there is no top-down enforcement of benchmarks for each country. The idea is that transparency will boost action: Countries submit their own pledges called nationally determined contributions (NDCs) every five years, and these plans are supposed to be increasingly ambitious, with the hope that they become strong enough to hold warming below 2 degrees. +
++Unfortunately, when Paris was adopted in 2015, the first round of pledges missed the mark. Climate Action Tracker estimated that the pledges would lead to 2.7 degrees Celsius of warming — to say nothing of what countries would actually manage to achieve. Which means a lot has been riding on the next round of pledges in 2020. +
++Obviously, this hasn’t been the 2020 that anyone had planned. Although all countries are supposed to submit new targets by the end of the month, many won’t file their plans until next year, ahead of the next major United Nations climate negotiations that were delayed due to the pandemic. +
++So far, only 22 countries have updated their NDCs, while 125 countries have pledged that they intend to improve their targets, according to Climate Watch. +
++But major new climate commitments from the European Union and the United Kingdom, among others, at last weekend’s virtual Climate Ambition Summit — held to mark the fifth anniversary of the Paris agreement — have increased the momentum heading into the new year. Chinese President Xi Jinping also announced updated NDC targets, which are a step forward, but not as ambitious as climate advocates had hoped. +
++“We are now seeing that countries are in fact ramping up ambition over time, and they are doing this despite some incredible hurdles that have been thrown up over the last few years, including the obviation of leadership from the US for a critical period of time,” said Taryn Fransen, a senior fellow in international climate governance at the World Resources Institute. +
++These new pledges from some of the world’s top emitters bring us closer to the Paris agreement goals, but a gap remains. In a video posted on Twitter last week, Swedish climate activist Greta Thunberg said, “the action needed is still nowhere in sight.” At this critical five-year anniversary, here’s where the agreement stands. +
++When it comes to cumulative emissions over time, the US, the EU, and China have contributed the greatest share, so they are key players in the Paris agreement. Since Trump announced the US would withdraw from it in 2017, the EU and China have helped ensure its survival. And at last weekend’s UN summit, European leaders made their biggest emission reduction commitments yet. +
++The UK — now broken out of the EU via Brexit — will host the 26th Conference of the Parties (COP 26), the major UN climate negotiations to be held in 2021. So its government was under particular pressure and scrutiny to come up with an ambitious new pledge. +
++Just before the summit in early December, the government announced a target to reduce its greenhouse gas emissions 68 percent from 1990 levels — a target it officially submitted as part of its new NDC during the Climate Ambition Summit. +
++According to Climate Action Tracker, this places the UK among the first countries to have an NDC that is compatible with the ambition of the Paris agreement, to keep temperature rise to 1.5 degrees Celsius. +
++At the summit, the EU also committed to an aggressive new goal, to reduce greenhouse gas emissions 55 percent below 1990 levels by 2030, up from the previous pledge of 40 percent. +
++EU leaders celebrated the commitment as a sign of Europe’s climate leadership. However, it falls slightly short of alignment with the Paris agreement’s 1.5 Celsius target, according to Climate Action Tracker (which estimates that a reduction somewhere between 58 and 70 percent would be needed). +
++Nonetheless, experts said these new commitments might help spur other countries to take more aggressive action than they’d been planning to. +
++“With the COP delayed to next year, ending this year with as many major economies that have seriously enhanced their NDC [as possible] is really important to put pressure on others to do that next year,” said Thom Woodroofe, a senior adviser to the president of the Asia Society Policy Institute and a former climate diplomat. +
++Of course, since China is the top emitter globally, its climate actions are central to the success of the Paris agreement. +
++In 2014, the US and China laid the foundation for the Paris agreement together, jointly announcing their targets ahead of the negotiations. Climate experts were relieved when China forged ahead after Trump announced the US would withdraw from the agreement. +
++Last weekend, Xi Jinping continued to make progress on climate, presenting a new set of targets at the Climate Ambition Summit. +
++These new pledges shouldn’t be taken for granted given the disruption of the pandemic and the breakdown in US-China relations, said Li Shuo, a senior climate policy officer at Greenpeace East Asia, during a webinar hosted by the Wilson Center China Environment Forum on Monday. “If we go simply back for a few months, many probably wouldn’t foresee any of those announcements, including the NDC enhancement, but also the carbon neutrality pledge,” he said, referring to Xi’s surprise announcement at the UN General Assembly in September that China will aim to be carbon-neutral by 2060. +
+ ++The updates Xi announced at the Climate Ambition Summit on Saturday are more complex than the EU and UK emissions reduction numbers, because China’s NDC spans four targets. Woodroofe summarizes the changes from China’s original NDC in the handy chart below. +
++++Xi Jinping just confirmed China will update all four quantifiable goals in its 2030 NDC, not just the peaking date. Here is my attempt to quickly put in context. Very little ambition overall - nothing on coal, BRI or non-CO2. Next Five Year Plan can do more. #ClimateActionSummit pic.twitter.com/MNKDUdqpLu +
+— Thom Woodroofe (@thomwoodroofe) December 12, 2020 +
+While the updates are a step forward, they could have gone further, said Woodroofe. “Really they are not headlining increases in ambition, and in many ways, they frankly replicate the trajectory that China is already on,” he said. +
++As he points out, Xi only committed to a subtle shift in the date when China will reach peak emissions from “around 2030” to “before 2030.” According to a study published by the Asia Society Policy Institute and Climate Analytics in November, China needs to peak its emissions by 2025 to be in line with the Paris agreement and its long-term emissions goals. +
++The carbon intensity target (a measure of carbon emissions per unit of GDP) would also have to be stronger than the new 65 percent baseline level Xi announced to be aligned with a 1.5-degree future. +
++On the more ambitious end, the new target for non-fossil fuel energy to reach 25 percent by 2030 (up from 20 percent) could spur much more aggressive renewable energy development, Lauri Myllyvirta wrote in Carbon Brief. +
++While the targets may be a boon for clean energy growth, they probably won’t cut significantly into fossil fuel use, Li said. China still has the largest number of coal power plants under development globally, which will lead to higher emissions, and none of the targets directly confront that issue. +
++The question remains: “How do we really find the political courage to say no to the long-standing development model that we have, which is heavily based on infrastructure investment and development?” according to Li. +
++China is likely to submit these new targets in an official NDC to the UN by the end of the year, he said, but there may be room for even more aggressive targets to be set in 2021. China will release its 14th Five-Year Plan in March, setting new economic, social, and environmental goals. And with President-elect Joe Biden taking office in January, China and the US are expected to reinstate diplomatic channels on climate change again. If the Biden administration can carry out bold climate action, that may give China the assurance it needs to be more ambitious as well. +
++But for now, “there is a big gap between what Xi has outlined China will do by 2030 and what he has outlined is his vision for China by 2060, and there is not an obvious way to reconcile that gap,” Woodroofe said. +
++Because the pandemic has disrupted the normal UN climate commitment cycle, it’s impossible to do a full accounting of how the Paris agreement has held up at its five-year anniversary. Countries will likely continue submitting updated NDCs until the next UN climate conference, COP 26, is held in November 2021. +
++But it is clear that China is not the only large economy to have a gap between its short-term targets and the long-term vision of decarbonization in line with the agreement. +
++In a statement published Saturday, Biden pledged that the US will rejoin the Paris agreement “on day one of my presidency”; he also committed to a long-term target of net-zero emissions by 2050. But the short-term target the US will put forward as its updated NDC once it rejoins Paris next year has yet to be announced. +
++“They are in a tough position because we have lost, essentially, four years under the current administration of going backward on climate action. So the Biden administration is going to need to come forward with something that will be viewed as ambitious enough to be credible by the international community,” said WRI’s Fransen, but “they will also need to come forward with something they can implement.” +
++Other Paris agreement laggards include Brazil and Russia, which submitted new NDCs but did not increase their stringency. Brazil actually submitted a new NDC that is weaker than its previous one, according to Fransen. Indonesia and Australia have also said they will not increase their ambition, Climate Action Tracker reports. Some significant emitters have committed to proposing higher targets but have yet to, including India. +
++The inaction — and in some cases backpedaling — from these countries is why Thunberg said on Saturday that the measures to make good on the Paris agreement are still not in sight. An increasing number of countries have committed to reaching net-zero emissions by 2050, but, for Thunberg, these are merely “‘hopeful’ distant hypothetical targets,” while more ambitious short-term targets are needed to get the ball rolling. +
++Meanwhile, Fransen noted that countries particularly threatened by climate change continued to put forward ambitious targets at the summit. These countries, including island nations like the Maldives, are a “moral beacon” for the rest of the world, she said. For several island nations, the Paris agreement’s success is an existential quest: Many may become uninhabitable if the global temperature rises by 1.5 degrees. +
++The UN Environment Program’s latest emissions gap report, based on NDCs as of November, shows that without further action we are heading toward 3 degrees Celsius of warming. +
++For the countries and communities around the world most vulnerable to climate change, whether that gap is closed by new pledges over the coming months will be the real test of the Paris agreement. +
++A vote on Tuesday was the latest flashpoint in the debate over the proper role for billionaire philanthropy. +
++Facebook CEO Mark Zuckerberg’s adopted hometown of San Francisco on Tuesday formally condemned the naming of a major hospital after him and his wife, the latest flashpoint in the debate over the proper role for billionaire philanthropy. +
++The city’s board of supervisors approved the condemnation, a move that reflects the new, increasingly controversial politics of both the tech industry and of its founders. Activists on both the left and the right have grown sharply critical of big tech companies like Facebook. And simultaneously, there is a building backlash movement to charitable gifts from the mega rich. +
++The 10-1 vote is a manifestation of each of those crosscurrents, which both run particularly strong in liberal San Francisco. The measure has no legal force and is merely symbolic. +
++Five years ago, Zuckerberg and his wife, Priscilla Chan, gave $75 million to San Francisco General Hospital, the city’s sole public hospital, where Chan was a pediatrician at the time. As part of the donation, the hospital was formally renamed the Priscilla Chan and Mark Zuckerberg San Francisco General Hospital and Trauma Center. +
++Since then, Zuckerberg has emerged as a political piñata as Facebook grew in size and has been dogged by cascading scandals. And Zuckerberg’s troubles in his corporate life have increasingly boomeranged onto his charitable gifts, most notably at his and his wife’s eponymous philanthropy, the Chan Zuckerberg Initiative. +
++And so after years of fits and starts, a group of hospital nurses, anti-Facebook activists, and progressive lawmakers on San Francisco’s board of supervisors began to mobilize this summer to push back against the hospital’s name. Rather than moving to officially rename it — which contractually could require returning the $75 million gift — the group decided to push for a middle ground: to condemn the name while leaving it in place. +
++The final vote on Tuesday followed an earlier vote this month by the Committee on Government Audit and Oversight, a panel on San Francisco’s board of supervisors. That’s when the measure was debated more fully. +
++“San Francisco’s only public hospital should not bear the name of a person responsible for endangering public health in our country and around the world — and yet it does,” said Gordon Mar, the lead sponsor of the measure. “These are policy choices, and they have a body count.” +
++“We’re of course thankful for the gift and we’re thankful for any gift to our most important institutions during this time,” said Matt Haney, another supervisor backing it. “But that doesn’t mean that we should for forever essentially have given away advertising rights on this most essential public institution.” +
++That session quickly became a pop-off session on the Facebook founder, with activists pillorying him for any corporate transgressions and downplaying the significance of his gift, which was the largest single private gift to a public hospital ever. The comments became quite caustic — for instance, one San Franciscan called him a “rich, amoral egotist who runs an extraction corporation.” +
++Meanwhile, charity leaders voiced concern over the precedent that the resolution could set. Defenders of high-dollar philanthropy often argue that regardless of any tax advantages or public-relations boons that the donation offers the giver, their money also does real good for the disadvantaged. And the hospital agreed in 2015 when it accepted the $75 million that it would keep the Zuckerberg name for at least 50 years. +
++Kim Meredith, the head of the hospital’s foundation, stressed that the “heartfelt gift” from Zuckerberg and Chan had made the city “a model of care” during the coronavirus pandemic. +
++“This resolution of condemnation on the naming of [the hospital] has the potential of unintended consequences and a chilling effect on past, present, and future gifts to the city,” she said. “We will need philanthropies to continue to tackle the challenges of Covid-19, health equity, and recovery in future years.” +
++Meredith added in a later statement that she was “proud that the hospital now bears their names.” +
++It is not unusual for an institution to name something after a donor who makes a particularly large gift. Another San Francisco hospital is named after a different tech billionaire, Salesforce founder Marc Benioff. San Francisco officials signed off on the Zuckerberg naming contract in 2015. +
++But for an institution to formally condemn a donor is unusual, if not unprecedented. +
++Vox reporter Umair Irfan joins Today, Explained to discuss the latest Covid-19 vaccine news. +
++It’s been a busy week in vaccine news: The FDA authorized the first Covid-19 vaccine in the US on December 11, and the vaccination campaign is underway. The first US health workers received the Pfizer/BioNTech Covid-19 vaccine on December 14. +
++With all of the news around coronavirus vaccines, of course, comes a lot of questions. Vox science reporter Umair Irfan joined Today, Explained in a live conversation with host Sean Rameswaram to answer some of the biggest questions from our podcast listeners. (A transcript of their conversation, lightly edited for length and clarity, follows below.) +
++
++The live podcast event also featured a conversation with Dr. Anthony Fauci. The nation’s leading infectious disease scientist spoke about everything from his personal reflections on the past year to what it will take to get to “true herd immunity.” +
++The Fauci segment of this live podcast event will air next week as part of the Today, Explained upcoming podcast series “You, Me, and Covid-19,” which looks back on how the coronavirus has fundamentally reshaped our world. Through reporting, listener reflections, and interviews, the team will examine how Covid-19 changed our relationships with one another and with the places we live, upended our livelihoods, and redefined what we think of as “normal.” +
++The first episode of the series drops on Monday, December 21, and continues throughout the week. Subscribe to Today, Explained wherever you listen to podcasts — including Apple Podcasts, Google Podcasts, and Spotify — so you don’t miss an episode. +
++The one thing to highlight is the unprecedented speed at which we have developed this. Vaccine development is something that typically takes decades. The fastest vaccine ever developed was the mumps vaccine that took four years. This was a disease we only discovered last year around this time. +
++And now about a year later, we already have a vaccine that’s starting to be distributed. So this is something that’s unprecedented in terms of science. And the other big thing to highlight is that this is also using a completely new technology. Both the Pfizer/BioNTech vaccine and the Moderna vaccines are using an approach [with] the RNA-based genetic material. This is something that we’ve never tried on large scales in humans before. +
++So the old-fashioned way of doing viruses or vaccines was you would take the virus — weaken it, kill it, or snip off a piece of it — and inject it into the body. And then your immune system would read that and develop a response. They would use it as sort of a punching bag to essentially prepare for when the virus actually invades. +
++What these new generations of vaccines are doing is you don’t need the virus at all. In fact, all you do is you start with the genetic material. That is the information used to code for how to make the virus. And you don’t even need to know how to make the whole virus. You only need to know how to make a piece of it, like the spike proteins. +
++So with the coronavirus, the spike proteins are really important because that’s what they use to break into cells. They’re kind of like lock picks. And so what [companies] like Moderna and Pfizer have done is they took the instructions in RNA and they basically inject those into the human body, into muscles, and then your own cells will read those instructions and then manufacture their own copies of those specific spike proteins. Then, your immune system will use that as target practice. +
++And so this is, again, something that we’ve never done before, but it’s extremely fast. The first mRNA vaccines were developed within days of the genetic sequence of the coronavirus being released publicly. And then within two months, they were tested in the first humans. +
++Let’s start backwards and work towards where we are now. Ultimately, we want everybody to be vaccinated against this as much as possible because this is a disease that can infect just about everybody. So that’s the ultimate goal post, trying to get as close to saturation. +
++But, of course, we can’t do that right away. So the Centers for Disease Control convened an advisory committee, and they looked at where would these vaccines be most effective, not just in terms of preventing deaths but also in terms of preventing spread. +
++If we can inoculate [people who are most likely to spread the virus to other people], we can control transmission. They found out that those people are likely going to be health workers. So the first priority on the list are logically going to be health workers, but also people who live in long-term care facilities, older adults, and particularly the people that work around them. +
++The idea is that these people can act as sort of firebreaks against this inferno of a pandemic. The problem, though, is when you add up those people just in those high-risk groups, that’s 24 million people. And we’re not going to have 24 million doses right away. The Operation Warp Speed estimates that will have just about 20 million Americans inoculated by the end of December. And that’s if everything goes perfectly well, which means that there will still be some people that will have to wait. +
++So it really is going to vary from state to state and even from region to region. Different states and different hospitals have their own guidelines. Some of them are developing an algorithm which sorts out who is at highest risk. Some of them are awarding vaccines based on a lottery system. Your odds of getting a vaccine — or when you will get it — really depend on your city, your state, how many vaccines they received, and how effectively they’re distributing them. +
+ ++Yes. Both the Moderna vaccine and the Pfizer/BioNTech vaccine are two-dose vaccines administered about several weeks apart. +
++Last week, before Pfizer/BioNTech received their emergency use authorization from the FDA, they released some of their data showing their trial pool. The data showed that they had about 160 some people who got infected with Covid-19 in the placebo group and about nine people that got infected in the group that got the vaccine. +
++But if you look at when they got infected, most of those nine people were infected just a few days after they received the first dose of the vaccine. So between the first and second dose, building up an immune response is something that can take several days up to a couple of weeks. It’s likely that they were still vulnerable in that window where they were infected. Basically, the vaccine hadn’t kicked in yet, and so they were able to get infected and get sick in that specific time frame. +
++Yes. There were a couple of people that, I think, were reported to have received the vaccine to have come down with Covid-19 after getting the second dose. Those will have to be investigated further; that’s why we don’t say this vaccine is 100 percent effective. Ninety-five percent effective is still very high. But it also means that not every single person who gets a vaccine is ultimately going to have protection, which means we still have to take some precautions even after getting vaccinated. +
++We’re still learning about them. Generally, we would expect most complications with vaccines to happen shortly after you get the vaccine. Even though we’re only getting the results of the phase 3 clinical trials in the past few weeks, you know, we’ve had phase 1 and phase 2 trial results for several months. So, we know for the most part that most people don’t really have a severe reaction to this. +
++The main side effects after getting the vaccine are going to be muscle pain, weakness, some redness and soreness, and a mild fever. Those are the most common complaints. We don’t really have good long-term safety data just simply for the fact that this virus and this vaccine [have] not been around very long. In order to get the emergency use authorization, Pfizer had to provide two months of safety data. But they’ve also committed to following their candidates in their phase 3 clinical trial for up to two years, basically actively monitoring them and tracking them. They’re also going to continue paying attention to people in the general population as they receive the vaccine. +
++Now, it’s very likely that any risks associated with this are very, very low, because vaccines are drugs that are tested to a very high standard. They go out of their way to make sure that complication rates are very low. Generally, these are some of the safest pharmaceutical drugs that we have ever developed. But again, the risk is not zero. There are some people that may experience some complications, and it’s worth trying to take steps ahead of time to try to minimize them, to see what risk factors lead to complications, and then also helping out the folks that do actually have any kind of trouble with them afterwards. +
++These vaccines are very effective against disease, meaning that they will prevent you from getting sick. But we don’t really know how well they prevent infection or transmission. It’s likely that the people who get vaccinated may be able to still spread this virus to other people. And that’s why behavior can’t really change that much from where it is right now. +
++[The vaccine is] useful in that we can keep people out of hospitals and from dying or getting seriously ill. But precautions like wearing masks and maintaining social distance, those are all going to be important even after the vaccines start rolling out. Even after you and I get vaccinated, we’re going to have to maintain that until transmission lowers enough to the point that we can start letting our foot off the accelerator here. And so that’s why we need to be really paying attention to this. +
++The other thing is, with vaccines, you don’t want to necessarily use that as an excuse to engage in risky behavior because, again, it’s 95 percent effective, not 100 percent effective. There’s potential for somebody who’s vaccinated to still get seriously ill, so it’s important to take precautions, even for your own sake. +
++Over time, we do expect some behavior change, things like allowing kids to go to school in person or allowing certain kinds of events or gatherings that are urgently needed, certain kinds of, like, academic programs or other things like that. And then allowing some people to go to work, for instance. Those changes will eventually start to happen as we get transmission down and as vaccination rates go up. But both of those things need to happen at the same time, and that’s going to take some time to do. +
++The recommendations right now are likely going to be that you still get the vaccine. The reason is that while being naturally infected with the virus gives you some degree of immunity and protection, it’s not necessarily targeted. The vaccines are optimized specifically to neutralize the virus and its infection and how it causes disease, whereas with your own natural infection, you will produce antibodies, but they’re more scattershot. They’ll target some of the parts of the virus that cause infection, but they’ll target other parts that don’t necessarily interfere with its reproduction cycle. So it’s very likely that most people, even if they have gotten sick with this, it would be useful for them to still get vaccinated. +
++What we’ve seen with the coronavirus in general is that most people don’t get seriously ill. And there’s a number of people that can have the virus and spread it without showing any symptoms at all. That means your immune system doesn’t even mount a response, and the virus doesn’t really do much damage to you. +
++It’s likely that even after your body gets coached to fight off this infection, the infection might be so low grade that it doesn’t really do anything. It doesn’t even trigger the alarm bells in your body, but it still allows you to spread the virus to other people. And that low level of infection or transmission still poses a risk. +
++Now, there’s some evidence, especially with Moderna’s data that was just put out today, that seems to indicate that their vaccine actually does lower transmission. So it’s very likely we would actually see a dent in transmission by getting this vaccine, but it’s not as steep of a drop as we saw with reductions in disease. You’ll likely have a lower risk of making other people sick, but not as low as the risk of keeping yourself from getting sick. +
++That’s really hard to say because children were explicitly excluded from these clinical trials. In fact, that was one of the big sources of contention during the meeting last week with the advisers to the Food and Drug Administration. They were looking at trial data, and they said that the youngest people in the trial were 16 years old and there weren’t that many of them. [The advisers] were wondering: “Is this a vaccine that we can approve for everyone over the age of 16, or should we raise that to everyone over the age of 18?” +
++They eventually approved language saying everyone over the age of 16. And it’s very likely that it will be safer in younger people. But with an emergency use authorization, you’re balancing risk and reward, because you’re looking at the potential benefit but you’re also looking at any potential harm. +
++Now, we know, for instance, that children are much less likely to get severely ill from this virus compared to, say, adults and much older adults. And looking at that risk-reward calculation right now, it seems that it doesn’t really weigh in favor of vaccinating children, [though] that could change in the future, as they do more trials and testing and as we learn more about the disease. But for now, we’re looking mainly at health workers and older adults. +
++It depends on how fast the virus mutates. What we’ve seen so far is that it tends to be pretty stable in the parts of the virus that we’re most concerned about. That likely means that protection will last for a few years. Our experiences with SARS and MERS show that protection against those viruses also lasts for a few years. But eventually, the virus will change enough, and you’ll have to restart the process. You might need a booster a few years from now if there is still an outbreak or an epidemic. But it’s very likely that once you get the vaccine, you’ll have some room to breathe easy for a while. +
++The [thing] to remember is that our actions do matter. I use the firebreak analogy. The vaccines are like cutting firebreaks, cutting clearings in a forest so that the fire doesn’t spread. But that really doesn’t do much if there’s already a huge inferno that’s blazing. Our goal right now is to reduce transmission as much as possible so that when a vaccine does roll out, it becomes that much more effective. +
++There’s this herd immunity threshold of 80 to 90 percent of people being immune … where the pandemic starts to fizzle out. But we start to see reductions around 30 to 40 percent. And that can happen if we do a good job of controlling transmission. Our actions right now to try to limit the spread of the virus will make it easier and more effective for when a vaccine does start being administered to people who are in the low-risk pools, maybe next spring and maybe into early summer. +
++You can listen to this full conversation — and all episodes of Today, Explained — wherever you listen to podcasts, including Apple Podcasts, Google Podcasts, and Spotify. +
++
++
+Zimbabwe to host 2023 ODI World Cup qualifiers - The ICC also announced the schedule of the World League 2 and the Challenge League
Australia vs India, 1st Test | India prefer Shaw over Gill, Saha instead of Pant - India face Aussie might in its first overseas Test with pink ball, at Adelaide Oval
Ajinkya Rahane will do a tremendous job in my absence, says Virat Kohli - Virat Kohli will head home for the birth of his first child after the day-night game, starting on Thursday, leaving Rahane to captain the side in the remaining three Tests.
I am representation of new India: Virat Kohli - “The way my personality and character is, I am the representation of new India.”
Bumrah and company will hope history repeats itself Down Under - India’s fast bowling attack, capable of crossing the 140kmph mark consistently, can match the best in the business
LDF bags Alappuzha municipality - It wrests the civic body from the UDF by winning 35 out of 52 seats
Rahul Gandhi, Congress members walk out of Parliamentary Committee on Defence meeting - The Committee chairman did not allow Mr. Gandhi to speak, following which the Congress leader decided to walk out
On Wednesday, India reported 387 COVID-19 case fatalities in the previous 24 hours - New cases per million population in India in the past seven days is one of the lowest in the world.
I-T Dept. searches pharma company, associated concerns in Chandigarh, Delhi, Mumbai - Evidence gathered on ‘benami’ entity acting as a conduit for the company
British Foreign Secretary says he ‘discussed’ farmers stir with Jaishankar - Joint vaccine effort, Indo-pacific cooperation, protests and Mallya return highlighted during India-UK talks
Covid-19: Europeans urged to wear masks for family Christmas - The WHO says Europe is at "high risk" of a new wave of infections in the New Year.
Germans start holiday lockdown - New restrictions come into force limiting festivities to the smallest of family gatherings.
Paris mayor mocks 'absurd' fine for hiring too many women - City mayor Anne Hidalgo mocks the "absurd" penalty for breaking equal employment rules.
Brexit: 'Narrow path' in view for trade deal - EU chief - The president of the EU Commission says the "next few days" will be decisive for trade negotiations.
Prato: The Italian town turning rags into new clothes - A small Italian town has built its fortune on transforming the world's old scraps into new clothes.
FDA authorizes use of a nonprescription home COVID test - Test works with a cellphone app that can alert local health authorities. - link
FDA releases data on Moderna’s COVID vaccine: It looks good [Updated] - Data drop comes ahead of a potential Emergency Use Authorization on Thursday. - link
Uber defends sexual assault victims’ privacy, gets fined $59 million - Victim rights group RAINN said Calif. request risks "re-traumatization of victims." - link
Apple’s watchOS 7.2 is out, offers new health and fitness metrics - Apple's health-monitoring claims go far beyond those from typical fitness gear. - link
iPhone factory workers say they haven’t been paid, cause millions in damages - Dramatic video shows employees smashing windows in response to pay disputes. - link
+He was decomposing. +
+ submitted by /u/NeercyLL
[link] [comments]
+I can never tell if he's coming or going. +
+ submitted by /u/Dizturbed-
[link] [comments]
+Edit: He actually just gave me five golden rings! Maybe he really does know me (: +
++Edit2: More birds again +
+ submitted by /u/pacos-ego
[link] [comments]
+The fire consumed both books and in a tragic twist he hadn’t even finished coloring the second one. +
+ submitted by /u/jhutto2
[link] [comments]
+How to tell this to my wife +
++Where to find a 1 year old baby +
+ submitted by /u/arena79ers
[link] [comments]